Kalana Ispat Limited (NSE:KALANA)
India flag India · Delayed Price · Currency is INR
43.05
+5.50 (14.65%)
At close: Jul 31, 2025

Theseus Pharmaceuticals Balance Sheet

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '24 Mar '24 Mar '23 Mar '22 Mar '21
Cash & Equivalents
330.8610.9613.788.0732.87
Short-Term Investments
-0.150.15--
Cash & Short-Term Investments
330.8611.1113.938.0732.87
Cash Growth
--20.25%72.64%-75.44%-
Accounts Receivable
42.0261.8612.8516.5818.34
Other Receivables
--0.150.190.19
Receivables
42.0261.861316.7718.53
Inventory
31.5554.0986.4336.4120.98
Prepaid Expenses
-0.090.130.10.11
Other Current Assets
29.8124.627.8123.9415.56
Total Current Assets
434.24151.77121.3185.2988.04
Property, Plant & Equipment
36.5436.840.4441.245.03
Other Long-Term Assets
-0-0--
Total Assets
470.88188.57161.75126.49133.07
Accounts Payable
9.7716.3122.6851.9658.43
Accrued Expenses
12.128.123.064.285.65
Short-Term Debt
7.0646.1486.1826.0622.92
Current Portion of Long-Term Debt
----3.37
Current Income Taxes Payable
-5.410.88-0.08
Other Current Liabilities
1.910.170.480.620.53
Total Current Liabilities
30.8676.14113.2882.9290.98
Long-Term Deferred Tax Liabilities
3.593.713.923.984.07
Other Long-Term Liabilities
-0--00-0
Total Liabilities
35.1480.41117.7887.5395.48
Common Stock
130.3981.01101010
Retained Earnings
305.3527.1533.9728.9627.6
Shareholders' Equity
435.74108.1643.9738.9637.6
Total Liabilities & Equity
470.88188.57161.75126.49133.07
Total Debt
7.0646.1486.1826.0626.29
Net Cash (Debt)
323.8-35.03-72.25-17.996.57
Net Cash Per Share
25.75-4.49-13.38-3.331.22
Filing Date Shares Outstanding
10.558.15.45.45.4
Total Common Shares Outstanding
10.558.15.45.45.4
Working Capital
403.3875.648.032.37-2.93
Book Value Per Share
41.2913.358.147.216.96
Tangible Book Value
435.74108.1643.9738.9637.6
Tangible Book Value Per Share
41.2913.358.147.216.96
Land
-1.471.471.471.47
Machinery
-52.352.1349.3949.39
Source: S&P Global Market Intelligence. Standard template. Financial Sources.